在阿尔茨海默氏症中,和β氨基酸会引起微质激活
Subashchandrabose Chinnathambi1, Anusree Adithyan1, Madhura Chandrashekar1
1Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore, Karnataka, India.
Advances in clinical chemistry
|August 23, 2025
概括
阿尔茨海默病涉及团和β粉样蛋白斑块, 由质细胞和问题驱动. 针对这些途径为这种神经退行性疾病提供了潜在的新疗法.
科学领域:
- 神经退行性疾病
- 细胞生物学
- 神经炎症
背景情况:
- 阿尔茨海默病 (AD) 的特征是高酸聚合物和粉样β (Aβ) 斑块.
- 对于神经元稳定性至关重要的tau蛋白在过化时脱离微管,导致神经纤维结和神经元功能受损.
- Aβ斑块启动一个级联,促进Tau过和激活质细胞 (微细胞和星球细胞).
研究的目的:
- 审查阿尔茨海默病进展中的Tau,Aβ和质细胞之间的复杂相互作用.
- 突出质细胞在阿尔茨海默病中的双重保护和有害作用.
- 探索针对阿尔茨海默病的主要病理途径的治疗策略.
主要方法:
- 关于阿尔茨海默病病变的文献综述.
- 对Tau病理,Aβ沉积,质细胞激活和失调之间的相互作用进行分析.
- 对阿尔茨海默病的治疗干预措施的当前研究综合.
主要成果:
- 最初是保护性的质细胞激活,通过慢性神经炎症和氧化应激变得有害.
- 通过促进过,线粒体功能障碍和Aβ生成,失调会加剧AD.
- ,Aβ和质细胞之间的相互作用是AD进展的核心,对神经元损伤有重大影响.
结论:
- 针对陶酸化,Aβ清除,质激活,平衡和线粒体功能是有前途的治疗途径.
- 了解Tau,Aβ和质细胞的多方面的作用对于开发有效的AD治疗至关重要.
- 专注于这些相互联系的新疗法有可能减缓阿尔茨海默病的进展并改善患者的治疗结果.
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
03:03Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260